Perente I, et al. - In this study including 116 eyes of 58 patients, researchers assessed vascularization end limit of the peripheral retina. They focused on vascular development patterns of patients at the late period with aggressive posterior retinopathy of prematurity (APROP) who received a single intravitreal injection of bevacizumab. Within 90–100 gestational week, they examined all patients with RetCam III and fluorescein angiography (FA). They found that 86.2% of overall patients (100/116 eyes) had abnormal vascular findings, including circumferential vessels (43.1%), abnormal vascular branching (25.9%), closely packed vascular shunts (6.8%), and vascular leakage (10.3%). For treatment decision at late period of APROP patients treated with bevacizumab, quantitative data were provided by FA. An increased risk for late complications was reported in relation to fluorescein leakage and persistent avascular areas still detected at FA at 90–100 gestational weeks. FA enabled detection of abnormalities that can not be detected by means of indirect ophthalmoscope, and FA was shown to have utility for follow-up and further treatments of APROP.